Benzocaine on MedWatch
This article was originally published in The Tan Sheet
Consumers and healthcare professionals should be aware of possible adverse events, particularly methemoglobinemia, related to benzocaine sprays, FDA states in a Public Health Advisory posted Feb. 13 on MedWatch. The sprays are used in certain minor medical procedures to locally numb the mouth and throat and some methemoglobinemia events have been due to improper dosing, the agency explains. "FDA is aware of the reported adverse events and is reviewing all available safety data, but at this time is not planning action to remove the drugs from the market," the agency states. The advisory only applies to benzocaine sprays for the mouth and throat and excludes exterior topical benzocaine sprays, FDA clarifies...
You may also be interested in...
Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.
I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.
China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.